Drug-Drug Interactions Affecting the Efficacy of Bridion
{"Image DocumentName": "Drug-Drug Interactions Affecting the Efficacy of Bridion", "Image ImageDescription": "No clinically relevant drug interactions have been reported with Bridion. Pharmacokinetic-pharmacodynamic simulations show that the following displacement interactions are possible: Toremifene. The recovery to T4/T1 ratio of 0.9 could be delayed in patients who have received toremifene on the same day of surgery. Intravenous administration of high-dose flucloxacillin  and fusidic acid. The recovery to T4/T1 ratio of 0.9 could be delayed in patients who receive these products in the preoperative phase. Administration of these products in the postoperative phase (6 hours) is to be avoided. Throughout the clinical trials, consisting of >2000 patients, no clinically relevant interactions were reported during the clinical development of Bridion. However, through the use of pharmacokinetic and pharmacodynamic simulation models, interactions with toremifene, hormonal contraceptives, high-dose flucloxacillin, and fusidic acid were discovered.1,2. The toremifene interaction involves a possible displacement of rocuronium or vecuronium due to the high affinity constant and relatively high plasma concentration associated with toremifene. As a result, the recovery to T4/T1 ratio of 0.9 could be delayed in patients who have received toremifene on the same day of surgery.1,2. The high dose-flucloxacillin (infusion of 500 mg or more) and fusidic acid interactions involve a possible displacement of rocuronium or vecuronium. As a result, the recovery to T4/T1 ratio to 0.9 could be delayed in patients who have received these products in the preoperative phase. The use of these products in the postoperative phase (6 hours) is to be avoided.1,2. References. 1. Integrated Summary of Safety. 2. Bridion\u00ae (sugammadex) [Summary of Product Characteristics]. N.V. Organon, Kloosterstraat 6, 5349 AB Oss, The Netherlands; August Data on file. Bridion\u00ae [summary of product characteristics]. Organon, Europe;  Infusion of 500 mg or more J P Mulier. 54.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}